Patents by Inventor Jakob Lind Tolborg

Jakob Lind Tolborg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20240141010
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • Acylated glucagon analogues
    Patent number: 11884713
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Acylated glucagon analogue
    Patent number: 11274136
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: March 15, 2022
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20220073583
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: July 7, 2021
    Publication date: March 10, 2022
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • Acylated glucagon analogues
    Patent number: 11091528
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 17, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Glucagon analogues and methods of use
    Patent number: 11034747
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: June 15, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20200157168
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 12, 2019
    Publication date: May 21, 2020
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • ACYLATED GLUCAGON ANALOGUE
    Publication number: 20200087372
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 13, 2019
    Publication date: March 19, 2020
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Leo THOMAS
  • Acylated glucagon analogues
    Patent number: 10457714
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 29, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 10406207
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 10, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • Acylated glucagon analogue
    Patent number: 10336802
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 2, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
  • Glucagon analogues
    Patent number: 10253081
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20190076506
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 22, 2018
    Publication date: March 14, 2019
    Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆK
  • GLUCAGON ANALOGUES
    Publication number: 20190055296
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 18, 2018
    Publication date: February 21, 2019
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • GLUCAGON ANALOGUES
    Publication number: 20180355010
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 4, 2018
    Publication date: December 13, 2018
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT
  • Acylated glucagon analogues
    Patent number: 10004786
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: June 26, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • Glucagon analogues
    Patent number: 9988429
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: June 5, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20180141990
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 24, 2018
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • Glucagon analogues
    Patent number: 9975939
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • ACYLATED GLUCAGON ANALOGUE
    Publication number: 20180094038
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 5, 2018
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Leo THOMAS